Effects of androgen therapy on adipose tissue and metabolism in older men.
Schroeder ET - J Clin Endocrinol Metab - 01-OCT-2004; 89(10): 4863-72
From NIH/NLM MEDLINE
NLM Citation ID:
15472177 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Clinical Trial; Journal Article; Randomized Controlled Trial
Language:
English
Author Affiliation:
Department of Medicine and Division of Infectious Diseases, University of Southern California, Los Angeles, California 90033, USA.
Authors:
Schroeder ET; Zheng L; Ong MD; Martinez C; Flores C; Stewart Y; Azen C; Sattler FR
Abstract:
We investigated the effects of oxandrolone on regional fat compartments and markers of metabolism. Thirty-two 60- to 87-yr-old men (body mass index, 28.1 +/- 3.4 kg/m(2)) were randomized to oxandrolone (20 mg/d; n = 20) or matching placebo (n = 12) treatment for 12 wk. Oxandrolone reduced total (-1.8 +/- 1.0 kg; P < 0.001), trunk (-1.2 +/- 0.6 kg; P < 0.001), and appendicular (-0.6 +/- 0.6 kg; P < 0.001) fat, as determined by dual energy x-ray absorptiometry. The changes in total and trunk fat were greater (P < 0.001) than the changes with placebo. By magnetic resonance imaging, visceral adipose tissue decreased (-20.9 +/- 12 cm(2); P < 0.001), abdominal sc adipose tissue (SAT) declined (-10.7 +/- 12.1 cm(2); P = 0.043), the ratio VAT/SAT declined from 0.57 +/- 0.23 to 0.49 +/- 0.19 (P = 0.002), and proximal and distal thigh SC fat declined [-8.3 +/- 6.7 cm(2) (P < 0.001) and -2.2 +/- 3.0 kg (P = 0.004), respectively]. Changes in proximal and distal thigh SC fat with oxandrolone were different than with placebo (P = 0.018 and P = 0.059). A marker of insulin sensitivity (quantitative insulin sensitivity check index) improved with oxandrolone by 0.0041 +/- 0.0071 (P = 0.018) at study wk 12. Changes in total fat, abdominal SAT, and proximal extremity SC fat were correlated with changes in fasting insulin from baseline to study wk 12 (r >or= 0.45; P < 0.05). Losses of total fat and SAT were greater in men with baseline testosterone of 10.4 nmol/liter or less (< testosterone low with men older overweight in syndrome metabolic the of components some for beneficial be may lipids affect adversely not does that androgen an therapy Thus, reversible. largely were changes these oxandrolone; treatment during each) 0.03 < (P="0.036)" liter mmol 0.97 - + 0.54 by increased cholesterol lipoprotein non-high-density and 0.67 0.57 low-density measured directly 0.21 -0.49 decreased high-density However, sensitivity. insulin estimates improvements associated tissue adipose peripheral abdominal regional reductions durable significant produced therefore, therapy, Androgen 0.02). sustained scanning absorptiometry x-ray energy dual fat extremity trunk, total, 83% oxandrolone, discontinuing after weeks Twelve respectively]. cm(2) 21.3 -2.9 vs. 14.3 -24.1 kg 0.8 -1.5 1.1 [-2.5 levels higher those than dl) ng 300>
Major Subjects:
- Adipose Tissue / * drug effects / * metabolism / pathology
- Aging / * metabolism
- Androgens / * administration & dosage / adverse effects
- Oxandrolone / * administration & dosage / adverse effects
Additional Subjects:
- Aged
- Body Composition
- Body Mass Index
- Energy Intake
- Energy Metabolism / drug effects
- Exercise
- Glucose / metabolism
- Humans
- Insulin / blood
- Insulin Resistance
- Lipids / metabolism
- Male
- Middle Aged
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
Chemical Compound Name:
(Androgens); (Lipids); 11061-68-0(Insulin); 50-99-7(Glucose); 53-39-4(Oxandrolone)
Grant ID:
M01-RR-00043 RR NCRR